

Robert A Kyle

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9461738/robert-a-kyle-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

472
papers

29,133
citations

73
h-index

167
g-index

488
ext. papers

34,482
ext. citations

5.5
avg, IF

6.71
L-index

#	Paper	IF	Citations
472	A simple additive staging system for newly diagnosed multiple myeloma.. <i>Blood Cancer Journal</i> , 2022 , 12, 21	7	4
471	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , 2022 ,	10.7	2
470	Suzanne Gros Noñ Plastic Surgery Pioneer and Advocate for Women's Rights.. <i>Mayo Clinic Proceedings</i> , 2022 , 97, 196-197	6.4	
469	Samuel Gridley Howe: Abolitionist, Physician, and Pioneer in Education of Children With Vision Loss and Mental Disability.. <i>Mayo Clinic Proceedings</i> , 2022 , 97, 633-635	6.4	
468	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	
467	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.. <i>Blood Cancer Journal</i> , 2022 , 12, 67	7	1
466	Commercial Advertising on Postage Stamps: The Curious Case of Dr Francis Macbean Stewart's Miracle Cure.. <i>Mayo Clinic Proceedings</i> , 2022 , 97, 1029-1032	6.4	
465	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. <i>Mayo Clinic Proceedings</i> , 2021 ,	6.4	2
464	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 1639-1639	2.2	2
463	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021 , 138, 2707-2707	2.2	
462	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNENIS). <i>Blood</i> , 2021 , 138, 1333-1333	2.2	
461	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021 , 138, 2700-2700	2.2	
460	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. <i>Blood</i> , 2021 , 138, 1617-1617	2.2	
459	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021 , 138, 819-819	2.2	
458	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021 , 138, 3805-3805	2.2	
457	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021 , 11, 186	7	1
456	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3760-3760	2.2	0

455	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021 , 138, 3773-3773	2.2	
454	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021 , 138, 3761-3761	2.2	
453	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
452	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1632-1632	2.2	
451	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1619-1619	2.2	
450	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021 , 138, 543-543	2.2	
449	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021 , 138, 1630-1630	2.2	
448	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021 , 138, 119-119	2.2	
447	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2650-2650	2.2	
446	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021 , 11, 192	7	10
445	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2021 ,	10.7	5
444	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2021 ,	10.7	1
443	M. Vera Peters: Pioneering Radiation Oncologist. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2927-2928	6.4	
442	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021 , 194, 496-507	4.5	12
441	James Till and Ernest McCulloch: Hematopoietic Stem Cell Discoverers. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 830-831	6.4	1
440	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 677-687	6.4	4
439	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021 , 11, 50	7	8
438	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8049-8049	2.2	

437	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e20016-e20016	2.2	2
436	Emile Letournel: Pioneer of Acetabular Surgery. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1379-1380	6.4	
435	Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism. <i>Redox Biology</i> , 2021 , 41, 101927	11.3	2
434	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021 , 96, 945-953	7.1	2
433	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1546-1577	6.4	8
432	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 451-460.e2	2	2
431	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 589.e1-589.e6		2
430	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021 , 106, 354-361	3.8	3
429	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 380-385	4.5	9
428	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 330-337	7.1	3
427	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 308-315	1.9	0
426	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021 , 62, 316-322	1.9	1
425	Kaare Nygaard: Surgeon, Scientist, Sculptor. <i>Mayo Clinic Proceedings</i> , 2021 , 96, e7-e8	6.4	
424	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021 , 35, 1428-1437	10.7	4
423	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Cancer Journal</i> , 2021 , 11, 26	7	3
422	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 377-387	6.4	3
421	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3011-3018	1.9	0
420	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021 , 96, 1131-1136	7.1	6

419	Albin Lambotte: Pioneer of Osteosynthesis (Bone Fixation). <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2012-2013	6.4	0
418	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. <i>Clinical Biochemistry</i> , 2021 , 97, 67-73	3.5	1
417	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021 , 195, 210-216	4.5	5
416	Dr John H. Watson: Sherlock Holmes' Companion and Biographer. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2500-2502	6.4	
415	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021 , 11, 158	7	1
414	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021 , 96, 446-454	7.1	3
413	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020 , 10, 124	7	1
412	Roald Dahl: Children's Book Author, Medical Device Inventor, Myelodysplastic Syndrome Patient, and Philanthropist. <i>Mayo Clinic Proceedings</i> , 2020 , 95, e119-e120	6.4	
411	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020 , 10, 52	7	4
410	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 944-954	6.4	0
409	Razi: Critical Thinker, and Pioneer of Infectious Disease and Ophthalmology. <i>Mayo Clinic Proceedings</i> , 2020 , 95, e53-e54	6.4	
408	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1297-1304	4.4	3
407	Recognizing "diagnostic futility" - stopping earlier to protect patients. <i>American Journal of Hematology</i> , 2020 , 95, 580-582	7.1	
406	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 637-642	7.1	6
405	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 20	7	18
404	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 4	7	12
403	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020 , 95, 497-502	7.1	27
402	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 596-601	2	3

401	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 27-28	2.2	
400	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 9-10	2.2	
399	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). <i>Blood</i> , 2020 , 136, 40-41	2.2	1
398	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020 , 136, 44-45	2.2	
397	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 15-16	2.2	
396	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020 , 136, 14-15	2.2	
395	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020 , 136, 6-7	2.2	
394	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. <i>Blood</i> , 2020 , 136, 15-16	2.2	
393	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 21-22	2.2	
392	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020 , 136, 31-32	2.2	0
391	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020 , 136, 37-38	2.2	
390	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. <i>Blood</i> , 2020 , 136, 1-2	2.2	
389	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020 , 136, 44-45	2.2	
388	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020 , 136, 48-49	2.2	0
387	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 30-31	2.2	2
386	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020 , 136, 7-8	2.2	1
385	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 12-13	2.2	2
384	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020 , 188, 394-403	4.5	23

383	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020 , 95, 4-9	7.1	6
382	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 53-56	2	5
381	Alexandre Yersin: Discoverer of the Plague Bacillus. <i>Mayo Clinic Proceedings</i> , 2020 , 95, e7-e8	6.4	5
380	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020 , 95, 310-315	7.1	16
379	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020 , 95, E60-E62	7.1	1
378	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	7.1	18
377	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020 , 34, 1373-1382	10.7	22
376	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020 , 34, 1472-1475	10.7	10
375	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020 , 34, 1135-1143	10.7	19
374	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020 , 9, 8895-8901	4.8	1
373	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 6581-6588	12.9	9
372	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020 , 95, 1280-1287	7.1	10
371	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020 , 10, 82	7	17
370	Fernando Figueira: Brazilian Public Health Champion. <i>Mayo Clinic Proceedings</i> , 2020 , 95, e97-e98	6.4	
369	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020 , 27, 13-16	2.7	21
368	MYC dysregulation in the progression of multiple myeloma. <i>Leukemia</i> , 2020 , 34, 322-326	10.7	56
367	Albert Schweitzer: Humanitarian With a "Reverence for Life". <i>Mayo Clinic Proceedings</i> , 2019 , 94, e91-e92	6.4	2
366	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 811-814	10.7	15

365	John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library. <i>Mayo Clinic Proceedings</i> , 2019 , 94, e45-e46	6.4	8
364	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. <i>Blood Cancer Journal</i> , 2019 , 9, 49	7	4
363	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2960-2967	1.9	2
362	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019 , 185, 701-707	4.5	10
361	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019 , 9, 32	7	22
360	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019 , 94, 751-756	7.1	6
359	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 465-471	6.4	47
358	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019 , 185, 254-260	4.5	8
357	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 1268-1272	10.7	4
356	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019 , 54, 353-367	4.4	51
355	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019 , 187, 588-594	4.5	26
354	Andreas Vesalius and De Fabrica. <i>Mayo Clinic Proceedings</i> , 2019 , 94, e67-e68	6.4	1
353	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019 , 26, 101-102	2.7	4
352	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019 , 125, 3574-3581	6.4	3
351	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019 , 134, 72-72	2.2	1
350	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019 , 134, 4334-4334	2.2	1
349	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4386-4386	2.2	2
348	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1905-1905	2.2	1

347	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019 , 134, 5523-5523	2.2	
346	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019 , 134, 1532-1532		
345	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4396-4396	2.2	
344	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019 , 134, 3080-3080	2.2	
343	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019 , 134, 2774-2774	2.2	
342	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1904-1904	2.2	
341	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019 , 134, 5532-5532	2.2	
340	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019 , 134, 1800-1800	2.2	1
339	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 2197-2197	2.2	
338	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019 , 134, 5490-5490	2.2	1
337	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). <i>Blood Cancer Journal</i> , 2019 , 9, 27	7	36
336	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, E141-E143	7.1	13
335	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019 , 33, 1273-1277	10.7	7
334	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 472-483	6.4	33
333	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 1930-1938	7.8	20
332	Luke Fildes and The Doctor. <i>Mayo Clinic Proceedings</i> , 2019 , 94, e131-e132	6.4	0
331	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. <i>Blood Cancer Journal</i> , 2019 , 9, 102	7	27
330	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. <i>Leukemia</i> , 2019 , 33, 499-507	10.7	4

329	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019 , 94, 424-430	7.1	5
328	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 790-794	10.7	16
327	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019 , 33, 730-738	10.7	11
326	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019 , 15, 45-59	14.9	189
325	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019 , 33, 527-531	10.7	30
324	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 531-536	10.7	60
323	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. <i>British Journal of Haematology</i> , 2019 , 184, 1014-1017	4.5	11
322	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 306-311	7.1	9
321	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018 , 32, 1421-1426	10.7	5
320	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018 , 32, 2240-2249	10.7	49
319	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 739-746	6.4	16
318	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 889-894	7.1	8
317	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2127-2132	4.7	12
316	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018 , 97, 1417-1425	3	43
315	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018 , 32, 1414-1420	10.7	9
314	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018 , 32, 1811-1815	10.7	18
313	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2018 , 378, 241-249	59.2	216
312	A role for bone turnover markers ECrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2431-2438	1.9	8

311	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018 , 53, 326-333	4.4	4
310	Reply to Castillo et al. <i>American Journal of Hematology</i> , 2018 , 93, E71-E73	7.1	2
309	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>Clinical Biochemistry</i> , 2018 , 51, 38-47	3.5	25
308	Risk of melanoma in patients with multiple myeloma: A Surveillance, Epidemiology, and End Results population-based study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 621-623	4.5	2
307	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 179-186	7.1	29
306	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 187-194	7.1	45
305	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018 , 93, 17-22	7.1	9
304	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. <i>Blood</i> , 2018 , 132, 1478-1485	2.2	93
303	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018 , 93, 1207-1210	7.1	1
302	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018 , 11, e006588	3.9	31
301	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 1384-1393	7.1	15
300	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2443-2449	4.7	8
299	MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. <i>American Journal of Hematology</i> , 2018 , 93, E368-E370	7.1	26
298	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 59	7	115
297	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018 , 132, 4460-4460	2.2	0
296	Daratumumab-based therapies in patients with AL amyloidosis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8053-8053	2.2	2
295	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8023-8023	2.2	
294	Natural history of del53 multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e20017-e20017	2.2	

293	Predictors of disease progression in smoldering Waldenström macroglobulinemia.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7571-7571	2.2	
292	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8045-8045	2.2	
291	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8030-8030	2.2	
290	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1912-1912	2.2	
289	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , 2018 , 132, 3228-3228	2.2	
288	Treatment Facility Volume and Outcomes in Waldenström Macroglobulinemia. <i>Blood</i> , 2018 , 132, 622-622	2.2	
287	Depth of Response in Waldenström Macroglobulinemia. <i>Blood</i> , 2018 , 132, 4141-4141	2.2	0
286	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3159-3159	2.2	
285	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3158-3158	2.2	
284	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4449-4449	2.2	
283	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018 , 132, 3226-3226	2.2	
282	Ibrutinib Therapy in Patients with Waldenström Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018 , 132, 1606-1606	2.2	1
281	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4497-4497	2.2	
280	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1902-1902	2.2	
279	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018 , 132, 5594-5594	2.2	
278	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018 , 132, 3227-3227	2.2	
277	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018 , 132, 5610-5610	2.2	
276	Immune System Profiling of Waldenström Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018 , 132, 4138-4138	2.2	

275	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018 , 132, 3268-3268	2.2	
274	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884	2.2	1
273	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4615-4615	2.2	
272	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3160-3160	2.2	2
271	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018 , 132, 4152-4152		1
270	Patient-Reported Outcome Driven Case Management System for Hematology In Prospective Study. <i>Blood</i> , 2018 , 132, 719-719	2.2	
269	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 812-818	2.2	69
268	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 116	7	38
267	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018 , 8, 125	7	17
266	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 1518-1523	7.1	15
265	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?. <i>American Journal of Clinical Pathology</i> , 2018 , 150, 168-176	1.9	4
264	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017 , 49, 545-551	1.5	27
263	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 435-440	7.1	10
262	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017 , 129, 82-87	2.2	41
261	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017 , 129, 2111-2119	2.2	181
260	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017 , 92, E164-E166	7.1	2
259	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 40-41	2.7	3
258	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 44-45	2.7	1

257	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017 , 92, E507-E512	7.1	3
256	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017 , 92, 668-673	7.1	46
255	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 578-598	6.4	88
254	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 549-554	7.1	18
253	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. <i>JAMA Oncology</i> , 2017 , 3, 1257-1265	13.4	82
252	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 908-917	6.4	43
251	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 178, 888-895	4.5	14
250	Multiple myeloma. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17046	51.1	484
249	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017 , 179, 98-105	4.5	12
248	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, 1146-1155	7.1	22
247	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 183-188	2.7	1
246	Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , 2017 , 179, 170-172	4.5	7
245	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8038-8038	2.2	1
244	Factors predicting organ response in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8048-8048	2.2	1
243	Natural history of t(11;14) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8014-8014	2.2	0
242	The use of proteasome inhibitors among patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e19530-e19530	2.2	
241	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8049-8049	2.2	
240	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8047-8047	2.2	

239	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e19532-e19532	2.2	
238	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8032-8032	2.2	
237	Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1014-20	15.1	269
236	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, 1129-1134	7.1	42
235	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , 2016 , 17, e328-e346	21.7	1155
234	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016 , 175, 77-86	4.5	41
233	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016 , 91, 473-5	7.1	20
232	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2082-2082	2.2	1
231	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2016 , 128, 2968-2968	2.2	3
230	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenström Macroglobulinemia. <i>Blood</i> , 2016 , 128, 2972-2972	2.2	2
229	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016 , 128, 3272-3272	2.2	1
228	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3317-3317	2.2	3
227	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016 , 128, 3337-3337	2.2	5
226	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016 , 128, 4627-4627	2.2	1
225	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8004-8004	2.2	1
224	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8015-8015	2.2	1
223	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. <i>World Journal of Transplantation</i> , 2016 , 6, 380-8	2.3	44
222	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8035-8035	2.2	

221	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7552-7552	2.2	1
220	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8062-8062	2.2	
219	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8016-8016	2.2	
218	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016 , 128, 5615-5615	2.2	
217	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016 , 128, 3273-3273	2.2	
216	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016 , 128, 3251-3251	2.2	
215	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. <i>Blood</i> , 2016 , 128, 5480-5480	2.2	1
214	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016 , 128, 1810-1810	2.2	
213	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1194-1194	2.2	
212	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016 , 128, 3269-3269	2.2	
211	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3338-3338	2.2	
210	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016 , 128, 3255-3255	2.2	
209	Outcome of Very Young (<40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016 , 128, 5576-5576	2.2	
208	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2187-2187	2.2	
207	Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. <i>Clinical Chemistry</i> , 2016 , 62, 1334-44	5.5	93
206	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016 , 91, 984-8	7.1	37
205	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016 , 101, 1102-9	6.6	9
204	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016 , 44, 32-9	2.7	13

203	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 447-52	2	19
202	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016 , 127, 2955-62	2.2	463
201	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 644-654	2	29
200	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1354-1361	6.4	30
199	Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 179-186	4.2	7
198	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016 , 91, 1123-1128	7.1	52
197	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1893-1899	4.7	19
196	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016 , 91, 585-9	7.1	40
195	Clinical course and prognosis of non-secretory multiple myeloma. <i>European Journal of Haematology</i> , 2015 , 95, 57-64	3.8	33
194	Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 587-96	6.4	70
193	Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1054-81	6.4	81
192	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>JAMA Oncology</i> , 2015 , 1, 174-5	13.4	6
191	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015 , 90, 524-8	7.1	25
190	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3741-9	2.2	130
189	Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 335-41	4.7	50
188	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015 , 90, 888-91	7.1	14
187	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015 , 90, 981-5	7.1	28
186	Evidence Against Routine Testing of Patients With Functional Gastrointestinal Disorders for Celiac Disease: A Population-based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1937-43	6.9	21

185	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3357-64	1.9	28
184	Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 181-7	4.1	17
183	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015 , 90, 181-6	7.1	60
182	Diagnosis of monoclonal gammopathy of renal significance. <i>Kidney International</i> , 2015 , 87, 698-711	9.9	261
181	Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. <i>Clinical Chemistry</i> , 2015 , 61, 360-7	5.5	47
180	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015 , 126, 1774-1774	2.2	5
179	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015 , 126, 1830-1830	2.2	1
178	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4197-4197	2.2	5
177	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. <i>Blood</i> , 2015 , 126, 703-703	2.2	1
176	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015 , 126, 3292-3292 ^{2.2}		
175	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015 , 126, 3317-3317	2.2	
174	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4176-4176	2.2	
173	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , 2015 , 126, 5303-5303	2.2	
172	A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. <i>Science</i> , 2014 , 343, 656-661	33.3	57
171	Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. <i>American Journal of Cardiology</i> , 2014 , 113, 1723-7	3	83
170	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014 , 92, 485-90	3.8	21
169	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. <i>Lancet Haematology, the</i> , 2014 , 1, e28-e36	14.6	31
168	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014 , 15, e538-48	21.7	2253

167	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 775-90	3.1	27
166	Remission of disseminated cancer after systemic oncolytic virotherapy. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 926-33	6.4	202
165	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 402-408.e1	4.7	79
164	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014 , 124, 907-12	2.2	83
163	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014 , 89, 1051-4	7.1	25
162	Protein electrophoresis and immunofixation for the diagnosis of monoclonal gammopathies. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2160-1	27.4	1
161	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 360-76	6.4	341
160	Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 184-6	2	9
159	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4319-24	2.2	146
158	Implantable cardioverter defibrillators in patients with cardiac amyloidosis. <i>Journal of Cardiovascular Electrophysiology</i> , 2013 , 24, 793-8	2.7	118
157	How I treat monoclonal gammopathy of renal significance (MGRS). <i>Blood</i> , 2013 , 122, 3583-90	2.2	197
156	Survival Outcomes Of Very Young (. <i>Blood</i> , 2013 , 122, 2136-2136	2.2	1
155	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013 , 122, 3095-3095	2.2	1
154	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013 , 122, 3117-3117	2.2	2
153	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , 2013 , 122, 3119-3119	2.2	3
152	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013 , 122, 407-407	2.2	10
151	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3209-3209	2.2	
150	Progression in smoldering Waldenström macroglobulinemia: long-term results. <i>Blood</i> , 2012 , 119, 4462-62.2		83

149	Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. <i>Mayo Clinic Proceedings</i> , 2012 , 87, 1071-9	6.4	71
148	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. <i>Blood</i> , 2012 , 120, 4292-5	2.2	362
147	Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. <i>Journal of Clinical Oncology</i> , 2012 , 30, 989-95	2.2	582
146	Targeted therapy of multiple myeloma. <i>Hematology</i> , 2012 , 17 Suppl 1, S125-8	2.2	5
145	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012 , 120, 3972-3972	2.2	6
144	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012 , 120, 946-946	2.2	1
143	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012 , 120, 448-448	2.2	
142	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. <i>Blood</i> , 2012 , 120, 934-934	2.2	
141	Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis. <i>Blood</i> , 2012 , 120, 1861-1861	2.2	
140	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. <i>Blood</i> , 2012 , 120, 2059-2059	2.2	
139	Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 12-8	6.4	141
138	Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 419-20	6.4	8
137	The definition of IgM multiple myeloma. <i>American Journal of Hematology</i> , 2011 , 86, 718-719	7.1	1
136	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011 , 117, 4701-5	2.2	323
135	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2011 , 118, 2887-2887	2.2	1
134	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 3981-3981	2.2	1
133	History of multiple myeloma. <i>Recent Results in Cancer Research</i> , 2011 , 183, 3-23	1.5	9
132	Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010 , 150, 28-38	4.5	74

131	Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 945-8	6.4	83
130	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. <i>Lancet, The</i> , 2010 , 375, 1721-8	4.0	249
129	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. <i>Blood</i> , 2010 , 116, 5126-9	2.2	125
128	Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. <i>American Journal of Hematology</i> , 2010 , 85, 171-3	7.1	54
127	Screening panels for detection of monoclonal gammopathies. <i>Clinical Chemistry</i> , 2009 , 55, 1517-22	5.5	213
126	The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. <i>Cancer</i> , 2009 , 115, 2155-61	6.4	8
125	IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 17-8		4.0
124	Treatment of multiple myeloma: a comprehensive review. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 278-88		117
123	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008 , 111, 2516-20	2.2	1753
122	Multiple myeloma. <i>Blood</i> , 2008 , 111, 2962-72	2.2	654
121	Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials. <i>Blood</i> , 2008 , 112, 5129-5129	2.2	2
120	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. <i>Blood</i> , 2008 , 112, 95-95	2.2	1
119	Increased Risk of Monoclonal Gammopathy in First-Degree Relatives of Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.. <i>Blood</i> , 2008 , 112, 1672-1672	2.2	
118	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. <i>Blood</i> , 2008 , 112, 1707-1707 ²		
117	Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenström's Macroglobulinemia. <i>Blood</i> , 2008 , 112, 2709-2709	2.2	0
116	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 1093-113, ix	3.1	28
115	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: emphasis on risk factors for progression. <i>British Journal of Haematology</i> , 2007 , 139, 730-43	4.5	82
114	Epidemiology of the plasma-cell disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 637-64	4.2	91

113	Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. <i>New England Journal of Medicine</i> , 2007 , 356, 2582-90	59.2	566
112	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. <i>Blood</i> , 2007 , 110, 241-241	2.2	1
111	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007 , 110, 2477-2477	2.2	1
110	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation.. <i>Blood</i> , 2007 , 110, 4778-4778	2.2	
109	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1492-1492	2.2	
108	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007 , 110, 2995-2995	2.2	
107	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. <i>Blood</i> , 2007 , 110, 4779-4779	2.2	
106	Treatment of multiple myeloma: an emphasis on new developments. <i>Annals of Medicine</i> , 2006 , 38, 111-5	1.5	12
105	Prevalence of monoclonal gammopathy of undetermined significance. <i>New England Journal of Medicine</i> , 2006 , 354, 1362-9	59.2	902
104	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2006 , 107, 3378-83	2.2	198
103	Monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2006 , 134, 573-8	1.5	160
102	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. <i>Blood</i> , 2006 , 108, 3493-3493	2.2	1
101	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. <i>Blood</i> , 2006 , 108, 3587-3587	2.2	
100	International staging system for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3412-20	2.2	1921
99	Monoclonal gammopathy of undetermined significance. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 6, 102-14		38
98	Monoclonal gammopathies of undetermined significance. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 689-707	4.2	24
97	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2005 , 106, 812-7	2.2	452
96	The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 3396-3396	2.2	5

95	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. <i>Blood</i> , 2005 , 106, 781-781	2.2	3
94	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. <i>Blood</i> , 2005 , 106, 3381-3381	2.2	
93	Response to Rituximab in Type II Cryoglobulinemia.. <i>Blood</i> , 2005 , 106, 3499-3499	2.2	
92	The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. <i>Blood</i> , 2005 , 106, 1545-1545	2.2	
91	Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3751-7	2.2	593
90	Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. <i>Cancer</i> , 2004 , 101, 2667-74	6.4	145
89	Multiple myeloma. <i>New England Journal of Medicine</i> , 2004 , 351, 1860-73	59.2	1159
88	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2004 , 104, 1881-7	2.2	266
87	Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004 , 104, 331-331	2.2	11
86	Presence of an Abnormal Serum Free Light Ratio Is an Independent Risk Factor for Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS).. <i>Blood</i> , 2004 , 104, 3647-3647	2.2	12
85	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. <i>Blood</i> , 2004 , 104, 1475-1475	2.2	
84	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. <i>Blood</i> , 2004 , 104, 928-928	2.2	
83	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. <i>Blood</i> , 2004 , 104, 1493-1493	2.2	
82	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2004 , 104, 2291-2291	2.2	
81	Localized AL amyloidosis of the colon: an unrecognized entity. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003 , 10, 36-41	2.7	22
80	Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2003 , 102, 3759-64	2.2	236
79	Monoclonal gammopathies of undetermined significance: a review. <i>Immunological Reviews</i> , 2003 , 194, 112-39	11.3	96
78	POEMS syndrome. <i>Clinical Lymphoma and Myeloma</i> , 2003 , 4, 186		

77	Review of 1027 patients with newly diagnosed multiple myeloma. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 21-33	6.4	1526
76	Monoclonal gammopathies of undetermined significance. <i>Reviews in Clinical and Experimental Hematology</i> , 2002 , 6, 225-52		23
75	Current therapy of multiple myeloma. <i>Internal Medicine</i> , 2002 , 41, 175-80	1.1	10
74	A long-term study of prognosis in monoclonal gammopathy of undetermined significance. <i>New England Journal of Medicine</i> , 2002 , 346, 564-9	59.2	1090
73	Primary Localized Amyloidosis of The bladder:: Experience With Dimethyl Sulfoxide Therapy. <i>Journal of Urology</i> , 2002 , 168, 1018-1020	2.5	35
72	Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. <i>Clinical Chemistry</i> , 2002 , 48, 655-657	5.5	94
71	Genomic abnormalities in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2002 , 100, 1417-1424	27	276
70	Diagnosis of multiple myeloma. <i>Seminars in Oncology</i> , 2002 , 29, 2-4	5.5	8
69	Henry Bence Jones--physician, chemist, scientist and biographer: a man for all seasons. <i>British Journal of Haematology</i> , 2001 , 115, 13-8	4.5	13
68	Amyloidosis: a convoluted story. <i>British Journal of Haematology</i> , 2001 , 114, 529-38	4.5	135
67	Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2001 , 68, 269-75	7.1	50
66	Update on the treatment of multiple myeloma. <i>Oncologist</i> , 2001 , 6, 119-24	5.7	18
65	Multiple myeloma: an odyssey of discovery. <i>British Journal of Haematology</i> , 2000 , 111, 1035-1044	4.5	1
64	Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis. <i>Leukemia and Lymphoma</i> , 2000 , 39, 391-5	1.9	11
63	Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. <i>Mayo Clinic Proceedings</i> , 2000 , 75, 1264-8	6.4	101
62	Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. <i>Journal of Clinical Oncology</i> , 1999 , 17, 262-7	2.2	68
61	Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1551-7	2.2	55
60	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. <i>Blood</i> , 1999 , 93, 1062-1066	16	147

59	Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. <i>Leukemia and Lymphoma</i> , 1999 , 35, 599-605	1.9	26
58	VIII International Symposium on Amyloidosis, August 7-11,1998, Rochester, MN. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1999 , 6, 59-62	2.7	
57	Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. <i>Archives of Pathology and Laboratory Medicine</i> , 1999 , 123, 106-7	5	98
56	Primary systemic amyloidosis with delayed progression to multiple myeloma 1998 , 82, 1501-1505		83
55	Primary plasmacytoma at the site of exit wounds after electrical injury. <i>American Journal of Hematology</i> , 1998 , 58, 77-9	7.1	7
54	Familial amyloid with a transthyretin leucine 33 mutation presenting with ascites. <i>American Journal of Hematology</i> , 1998 , 59, 249-51	7.1	5
53	Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. <i>British Journal of Haematology</i> , 1998 , 100, 326-7	4.5	11
52	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. <i>British Journal of Haematology</i> , 1998 , 101, 296-301	4.5	63
51	Chromosomal abnormalities in systemic amyloidosis. <i>British Journal of Haematology</i> , 1998 , 103, 704-10	4.5	42
50	Multiple myeloma in young patients: clinical presentation and treatment approach. <i>Leukemia and Lymphoma</i> , 1998 , 30, 493-501	1.9	81
49	Primary systemic amyloidosis with delayed progression to multiple myeloma 1998 , 82, 1501		2
48	A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. <i>New England Journal of Medicine</i> , 1997 , 336, 1202-7	59.2	542
47	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997 , 90, 340-345	2.2	55
46	Identification of monoclonal proteins in serum: a quantitative comparison of acetate, agarose gel, and capillary electrophoresis. <i>Electrophoresis</i> , 1997 , 18, 1775-80	3.6	41
45	Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). <i>American Journal of Hematology</i> , 1997 , 56, 288-93	7.1	43
44	Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. <i>Human Mutation</i> , 1997 , 9, 83-5	4.7	10
43	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997 , 90, 340-345	2.2	4
42	Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. <i>Liver Transplantation</i> , 1996 , 2, 375-82		60

41	Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. <i>British Journal of Haematology</i> , 1996 , 93, 345-51	4.5	147
40	Multiple Myeloma: An Overview in 1996. <i>Oncologist</i> , 1996 , 1, 315-323	5.7	4
39	Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest?. <i>Leukemia and Lymphoma</i> , 1995 , 19, 417-22	1.9	7
38	Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?. <i>British Journal of Haematology</i> , 1995 , 90, 459-61	4.5	20
37	Monoclonal proteins and renal disease. <i>Annual Review of Medicine</i> , 1994 , 45, 71-7	17.4	32
36	Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. <i>British Journal of Haematology</i> , 1994 , 87, 266-72	4.5	77
35	IgD monoclonal gammopathy with long-term follow-up. <i>British Journal of Haematology</i> , 1994 , 88, 395-6	4.5	29
34	Expression of shared idiotypes by paraproteins from patients with monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 1994 , 87, 719-24	4.5	2
33	Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. <i>Cancer</i> , 1993 , 72, 108-13	6.4	62
32	Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type. <i>American Journal of Clinical Pathology</i> , 1992 , 97, 250-3	1.9	60
31	Mu-heavy chain disease: presentation as a benign monoclonal gammopathy. <i>American Journal of Hematology</i> , 1992 , 40, 56-60	7.1	34
30	Neuropathy associated with monoclonal gammopathies of undetermined significance. <i>Annals of Neurology</i> , 1991 , 30, 54-61	9.4	204
29	Computed tomography for diagnosis of hepatic rupture in primary systemic amyloidosis. <i>American Journal of Hematology</i> , 1991 , 37, 194-6	7.1	32
28	Speech disorders in systemic amyloidosis. <i>International Journal of Language and Communication Disorders</i> , 1991 , 26, 201-6	2.9	9
27	Cranial neuropathy associated with primary amyloidosis. <i>Annals of Neurology</i> , 1991 , 29, 451-4	9.4	46
26	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>European Journal of Haematology</i> , 1989 , 51, 70-5	3.8	5
25	Amyloid localized to tenosynovium at carpal tunnel release. Natural history of 124 cases. <i>American Journal of Clinical Pathology</i> , 1989 , 91, 393-7	1.9	50
24	Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. <i>American Journal of Hematology</i> , 1989 , 32, 226-9	7.1	16

23	IgD multiple myeloma: a cure at 21 years. <i>American Journal of Hematology</i> , 1988 , 29, 41-3	7.1	25
22	Prognostic factors in multiple myeloma. <i>Hematological Oncology</i> , 1988 , 6, 125-30	1.3	22
21	Monoclonal proteins in chronic lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , 1987 , 87, 385-8	1.9	38
20	Plasma cell leukemia: an evaluation of response to therapy. <i>American Journal of Medicine</i> , 1987 , 83, 1062-4	2.4	143
19	Synovial fluid analysis for diagnosis of amyloid arthropathy. <i>Arthritis and Rheumatism</i> , 1987 , 30, 419-23		24
18	Primary amyloidosis (AL) in families. <i>American Journal of Hematology</i> , 1986 , 22, 193-8	7.1	12
17	A monoclonal antibody reactive with a subset of human plasma cells. <i>British Journal of Haematology</i> , 1986 , 62, 619-30	4.5	19
16	Multiple myeloma: current therapy and a glimpse of the future. <i>Scandinavian Journal of Haematology</i> , 1985 , 35, 38-47		14
15	A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. <i>Cytometry</i> , 1985 , 6, 506-12		91
14	Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. <i>American Journal of Cardiology</i> , 1985 , 55, 1645	3	109
13	Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. <i>American Journal of Medicine</i> , 1985 , 79, 708-16	2.4	138
12	Factor-X deficiency in amyloidosis: a critical review. <i>American Journal of Hematology</i> , 1981 , 11, 443-50	7.1	131
11	Immunoperoxidase staining of bone marrow sections. <i>Cancer</i> , 1981 , 48, 2438-46	6.4	22
10	Amyloidosis: Part 3. <i>International Journal of Dermatology</i> , 1981 , 20, 75-80	1.7	8
9	Amyloidosis: Part 1. <i>International Journal of Dermatology</i> , 1980 , 19, 537-9	1.7	8
8	Factor X deficiency in primary amyloidosis: resolution after splenectomy. <i>New England Journal of Medicine</i> , 1979 , 301, 1050-1	59.2	97
7	IgG subclasses: relationship to clinical aspects of multiple myeloma and frequency distribution among M-components. <i>Scandinavian Journal of Haematology</i> , 1974 , 12, 60-8		19
6	IgG Cryoglobulinemia Associated With Amyloidosis. <i>Blood</i> , 1973 , 41, 569-576	2.2	3

5	Incidence of Monoclonal Proteins in a Minnesota Community With a Cluster of Multiple Myeloma. <i>Blood</i> , 1972 , 40, 719-724	2.2	164
4	"Intermediate" Cell Types and Mixed Cell Proliferation in Multiple Myeloma: Electron Microscopic Observations. <i>Blood</i> , 1966 , 27, 212-226	2.2	30
3	Orthostatic hypotension as a clue to primary systemic amyloidosis. <i>Circulation</i> , 1966 , 34, 883-8	16.7	39
2	Porphyria Cutanea Tarda Associated with Chronic Granulocytic Leukemia Treated with Busulfan (Myleran). <i>Blood</i> , 1964 , 23, 776-785	2.2	27
1	"Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. <i>Archives of Internal Medicine</i> , 1961 , 107, 344-53		78